BT5
2021-07-26

$Iterum Therapeutics Plc(ITRM)$ The FDA is scheduled to announce its decision on Iterum Therapeutics PLC's (NASDAQ: ITRM) NDA for oral sulopenem for the treatment of uncomplicated urinary tract infections in patients with a quinolone non-susceptible pathogen.

免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。

精彩评论

发表看法
4
1